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Aim
This presentation will review the concept of the inhibi-
tory quotient and its use in HIV pharmacology.
Materials and methods
Recent publications including research articles, abstracts
and review articles were retrieved to provide an over-
view of recent advances in the field.
Results
The inhibitory quotient is the ratio of drug exposure to
viral susceptibility. There are a number of different ways
to calculate the inhibitory quotient. The trough concen-
tration is the most frequently used pharmacokinetic
parameter to represent drug exposure in inhibitory quo-
tient calculations. To represent resistance, both pheno-
t y p i ca n dg e n o t y p i cd a t ac a nb eu s e dt oc a l c u l a t et h e
inhibitory quotient. Using population averages for drug
exposure and resistance it is possible to compare the
inhibitory quotient of different drugs. More frequently
the inhibitory quotient is used in the context of thera-
peutic drug monitoring. The inhibitory quotient has
mainly been studied for protease inhibitors. For non-
nucleoside reverse transcriptase inhibitors a single muta-
tion can cause high level resistance, whereas for PIs,
mutations have a smaller but cumulative effect. For this
reason it is unlikely that the inhibitory quotient will be
helpful in the therapeutic drug monitoring of non-
nucleoside reverse transcriptase inhibitors. For the
newer drugs in the classes of CCR5 and integrase inhibi-
tors it is not yet clear what the role for inhibitory quoti-
ent could be. In terms of therapeutic drug monitoring
cutoff values have been proposed for the genotypic inhi-
bitory quotient as well as for the phenotypic inhibitory
quotient.
Discussion
The inhibitory quotient has been topic of discussion for
the past decade. We have moved from the initial discus-
sions on how to compare inhibitory quotients for differ-
ent drugs into the use of inhibitory quotient as a useful
parameter for therapeutic drug monitoring. Further data
are needed to confirm the respective roles of different
forms of inhibitory quotient in daily practice.
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